LabGenius Therapeutics Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
70
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$13.5M
- Investors
-
34
LabGenius Therapeutics General Information
Description
Developer of next-generation protein-based therapeutics designed to address unmet needs like inflammatory bowel disease. The company's therapeutics engineer protein drugs properties, such as protease stability and tissue penetration, using their smart robotic platform to design, conduct, and critically learning from its experiments, enabling physicians to get access to protein therapeutics that are developed using robotic automation, synthetic biology, and advanced machine learning.
Contact Information
Website
www.labgeniustx.comCorporate Office
- G04 Cocoa Studios, The Biscuit Factory
- 100 Drummond Road
- London SE16 4DG
- England, United Kingdom
Corporate Office
- G04 Cocoa Studios, The Biscuit Factory
- 100 Drummond Road
- London SE16 4DG
- England, United Kingdom
LabGenius Therapeutics Timeline
LabGenius Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC (Series B) | 31-Jul-2025 | $13.5M | Completed | Pre-Clinical Trials | ||
| 9. Later Stage VC (Series B) | 01-Apr-2024 | Completed | Pre-Clinical Trials | |||
| 8. Grant | 30-Nov-2022 | Completed | Pre-Clinical Trials | |||
| 7. Later Stage VC (Series A) | 29-Oct-2020 | Completed | Pre-Clinical Trials | |||
| 6. Grant | 01-Jul-2020 | Completed | Pre-Clinical Trials | |||
| 5. Seed Round | 24-Nov-2017 | Completed | Pre-Clinical Trials | |||
| 4. Accelerator/Incubator | Completed | Startup | ||||
| 3. Grant | 01-Oct-2017 | Completed | Startup | |||
| 2. Grant | 09-Dec-2015 | $75.7K | Completed | Startup | ||
| 1. Grant | 01-Jun-2015 | $30.9K | Completed | Startup |
LabGenius Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference | ||||||||
| Series B2 | ||||||||
| Series B1 | ||||||||
| Series A2 Preferemce | ||||||||
| Series A2 Preferemce | ||||||||
| Series A1 Preference | ||||||||
| Ordinary | 173,900 | $0.002532 | $1.08 | $1.08 | 1x | $1.08 | 3.85% | |
| Preference | 228,322 | $0.002532 | $12.46 | $12.46 | 1x | $12.46 | 5.06% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
LabGenius Therapeutics Comparisons
Industry
Financing
Details
LabGenius Therapeutics Competitors (21)
One of LabGenius Therapeutics’s 21 competitors is ProteinQure, a Venture Capital-Backed company based in Toronto, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ProteinQure | Venture Capital-Backed | Toronto, Canada | ||||
| Genialis | Venture Capital-Backed | Boston, MA | ||||
| Sygnature Discovery | Private Equity-Backed | Nottingham, United Kingdom | ||||
| Horizon Discovery | Formerly VC-backed | Cambridge, United Kingdom | ||||
| Numerion Labs | Venture Capital-Backed | San Francisco, CA |
LabGenius Therapeutics Patents
LabGenius Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3139359-A1 | Methods and systems for protein engineering and production | Pending | 09-May-2019 | ||
| EP-3966825-A1 | Methods and systems for protein engineering and production | Pending | 09-May-2019 | ||
| GB-201906566-D0 | Methods and systems for protein engineering and production | Inactive | 09-May-2019 | ||
| US-20220064634-A1 | Methods and systems for protein engineering and production | Pending | 09-May-2019 | ||
| WO-2020225576-A1 | Methods and systems for protein engineering and production | Inactive | 09-May-2019 | G16B35/10 |
LabGenius Therapeutics Signals
LabGenius Therapeutics Investors (34)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Berggruen Holdings | Family Office | Minority | ||
| LG | Holding Company | Minority | ||
| Meltwind Advisory | Venture Capital | Minority | ||
| M Ventures | Corporate Venture Capital | Minority | ||
| Octopus Ventures | Venture Capital | Minority |
LabGenius Therapeutics FAQs
-
When was LabGenius Therapeutics founded?
LabGenius Therapeutics was founded in 2012.
-
Where is LabGenius Therapeutics headquartered?
LabGenius Therapeutics is headquartered in London, United Kingdom.
-
What is the size of LabGenius Therapeutics?
LabGenius Therapeutics has 70 total employees.
-
What industry is LabGenius Therapeutics in?
LabGenius Therapeutics’s primary industry is Drug Discovery.
-
Is LabGenius Therapeutics a private or public company?
LabGenius Therapeutics is a Private company.
-
What is the current valuation of LabGenius Therapeutics?
The current valuation of LabGenius Therapeutics is .
-
What is LabGenius Therapeutics’s current revenue?
The current revenue for LabGenius Therapeutics is .
-
How much funding has LabGenius Therapeutics raised over time?
LabGenius Therapeutics has raised $93.4M.
-
Who are LabGenius Therapeutics’s investors?
Berggruen Holdings, LG, Meltwind Advisory, M Ventures, and Octopus Ventures are 5 of 34 investors who have invested in LabGenius Therapeutics.
-
Who are LabGenius Therapeutics’s competitors?
ProteinQure, Genialis, Sygnature Discovery, Horizon Discovery, and Numerion Labs are some of the 21 competitors of LabGenius Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process